The efficacy of regorafenib combined with PD-1/PD-L1 inhibitor in advanced or metastatic colorectal cancer: A single arm meta-analysis.

ABSTRACT:

Background

Regorafenib alone has shown limited efficacy in some cases of colorectal cancer (CRC), while the use of programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors is becoming increasingly common in cancer treatment. Previous studies have indicated significant benefits of combining regorafenib with PD-1/PD-L1 inhibitors in patients with advanced or metastatic CRC. This study aimed to evaluate the efficacy and outcomes of combining regorafenib with PD-1/PD-L1 inhibitors in patients with advanced or metastatic CRC.

Methods

We systematically retrieved clinical trials from PubMed and Embase up to August 1, 2023. The quality of eligible clinical trials was assessed using the methodological index for non-randomized studies and the JBI critic

SUBMITTER: Yang F 

PROVIDER: S-EPMC12851704 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature